The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype.
The value of an abnormal serum CA125 test in the diagnosis of early ovarian cancer remains undetermined. In this series the level of serum CA125 was measured for patients with early cancer and also those with borderline ovarian tumours.
The sensitivity of an abnormal CA125 level with stage I ovarian cancer was low at 54%, meaning 46% were falsely negative. However, the likelihood of an abnormal serum CA125 level with benign ovarian tumour is low at 1.29 suggesting only three per hundred benign tumours will have abnormal serology.
Stage I endometrioid ovarian cancers; most commonly found in endometriosis patients, have a greater sensitivity with only 28% false negative serum CA125 serology.
No comments:
Post a Comment